

## Supplementary material

**Supplementary Table 1** Eligibility criteria.**Inclusion criteria**

- Histologically and/or cytologically proven locally advanced (stage II or III) or metastatic (stage IV) pancreatic adenocarcinoma
- Inoperable pancreatic cancer due to at least one of the following: a) unresectability; b) metastatic disease; c) medically unfit for surgery
- Single foci of tumor in the pancreas
- Platelet count  $\geq 50,000/\text{mm}^3$
- International normalized ratio of prothrombin time  $\leq 1.5$
- ECOG performance status  $\leq 2$
- Measurable lesion per RECIST (version 1.1) criteria
- Maximum lesion of 4 cm in the longest diameter (including primary tumor and regional lymph nodes)
- $\geq 18$  years of age
- Estimated life expectancy of at least 12 weeks
- Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test
- Subjects are willing to sign an informed consent

**Exclusion criteria**

- Multifocal pancreatic adenocarcinoma
- Contrast medium sensitivity precluding the subject from undergoing contrast enhanced CT
- Prior abdominal radiation therapy
- Concomitant chemotherapy or immunotherapy
- Borderline unresectable pancreatic cancer and medically fit for surgery
- Connective tissue disease (scleroderma, lupus)
- Prior chemotherapy does not exclude the patient
- Patients with significant comorbidities that the treating physician deems may conflict with the endpoints of the study (e.g., poorly controlled autoimmune diseases, vasculitis, etc.)
- Patients undergoing systemic immunosuppressive therapy excepting intermittent, brief use of systemic corticosteroids
- Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT
- High probability of protocol non-compliance (in opinion of investigator)
- Patients not willing to sign an informed consent form
- Women who are pregnant or lactating

CT, computed tomography; DaRT, diffusing alpha-emitters radiation therapy; ECOG, Eastern Cooperative Oncology Group; RECIST, Response Evaluation Criteria in Solid Tumors.